NCT06550687 Study of Cancer Patients' Preferences for Genetic Information Modalities Preceding Theranostic Exome Analysis.
| NCT ID | NCT06550687 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Georges Francois Leclerc |
| Condition | All Types of Metastatic Solid Malignancy |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2024-09-19 |
| Primary Completion | 2026-11-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2024-09-19 with a primary completion date of 2026-11-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Currently, the EXOMA2 study (NCT04614480) offers earlier and more comprehensive exome analysis in the management of cancer patients than EXOMA. Based on the active EXOMA2 patient file, the INFOGene study offers the opportunity to study patient-physician communication, to assess patient preferences with regard to different information modalities concerning theranostic exome analysis, and to reflect on information modalities to ensure optimal patient comprehension of the information provided. The qualitative cross-sectional study includes a dual observational and interventional component involving cancer patients. The patients will come from the EXOMA 2 active file at Dijon University Hospital and the CGFL.
Eligibility Criteria
Inclusion Criteria: * Patient identified for inclusion in the EXOMA 2 study (exome analysis request) * Available to receive different types of information * Fluent in French * No prior oncogenetic consultation * Having been informed of the objectives of the study and having given written non-objection to participate in the INFOGene study * Authorizing audio recording of consultations and interviews Exclusion Criteria: * Patient who refused to participate in the EXOMA2 study (for phase 3 patients only) * Has a psychiatric, cognitive or neurological disorder that makes participation impossible * Working in the field of genetics
Frequently Asked Questions
Who can join the NCT06550687 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying All Types of Metastatic Solid Malignancy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06550687 currently recruiting?
Yes, NCT06550687 is actively recruiting participants. Visit ClinicalTrials.gov or contact Centre Georges Francois Leclerc to inquire about joining.
Where is the NCT06550687 trial being conducted?
This trial is being conducted at Dijon, France, Dijon, France.
Who is sponsoring the NCT06550687 clinical trial?
NCT06550687 is sponsored by Centre Georges Francois Leclerc. The trial plans to enroll 80 participants.